Hi All
Thanks for all your replies, and yes, my question was in relation to the approval pathway for gvhd for kids, in a hypothetical scenario where the FDA accepts in the upcoming meeting the additional potency assay that's been provided by MSB as satisfactory response to its complete response letter. Sorry for posting this question in the wrong thread (must have been the reason for the confusion), but I just wanted some clarity on, in this hypothetical scenario:
1. Does MSB have to submit a new BLA including the additional assay and be subjected to the normal review period, or does MSB have the benefit of a rolling review for gvhd for kids as well?
2. In either case, what would be the anticipated review period by the FDA to grant full approval on gvhd for kids?
3. Assuming FDA is not going to approve gvhd for kids "on the spot" (i.e. at the meeting) as it will be subject to a review process, what is the "best" ASX announcement that we can expect to hear from MSB after the meeting?
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-252
-
-
- There are more pages in this discussion • 298 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 87395 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 274051 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 87395 | 0.985 |
3 | 116426 | 0.980 |
2 | 84419 | 0.975 |
3 | 54211 | 0.970 |
5 | 98141 | 0.965 |
Price($) | Vol. | No. |
---|---|---|
1.000 | 274051 | 2 |
1.005 | 49212 | 4 |
1.010 | 31212 | 2 |
1.015 | 72652 | 4 |
1.020 | 560 | 1 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |